Avitinib
CAS No. 1557267-42-1
Avitinib( AC-0010 | AC0010 )
Catalog No. M12212 CAS No. 1557267-42-1
Avitinib (AC-0010, AC0010) is an orally available, irreversible, and mutant-selective EGFR inhibitor with IC50 of 0.18 nM against EGFR L858R/T790M.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 37 | In Stock |
|
5MG | 60 | In Stock |
|
10MG | 105 | In Stock |
|
25MG | 205 | In Stock |
|
50MG | 335 | In Stock |
|
100MG | 494 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAvitinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionAvitinib (AC-0010, AC0010) is an orally available, irreversible, and mutant-selective EGFR inhibitor with IC50 of 0.18 nM against EGFR L858R/T790M.
-
DescriptionAvitinib (AC-0010, AC0010) is an orally available, irreversible, and mutant-selective EGFR inhibitor with IC50 of 0.18 nM against EGFR L858R/T790M; displays 43-fold greater potency over wild-type EGFR (IC50=7.68 nM); selectively inhibits mutant EGFR phosphorylation (IC50 =7.3 nM and 2.8 nM) in NCI-H1975 and NIH/3T3_TC32T8 cells, 115- and 298-fold more sensitive than that of the inhibition of wild type EGFR in A431; overcomes T790M-induced resistance in animal models and lung cancer patients without hyperglycemia or other severe adverse effects.Lung Cancer Phase 2 Clinical(In Vitro):Avitinib is structurally distinct from previously reported pyrimidine-based irreversible EGFR inhibitors such as osimertinib and rociletinib. Avitinib is designed specifically to inhibit EGFR active mutations and the T790M acquired resistant mutation, while sparing wild type EGFR. Avitinib selectively inhibits EGFR active and T790M mutations with up to 298-fold increase in potency compared to wild-type EGFR. Avitinib exhibits potent inhibitory activity with IC50 value of 0.18 nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type EGFR (IC50=7.68 nM). Avitinib selectively inhibits mutant EGFR phosphorylation with IC50 values of 7.3 nM and 2.8 nM in NCI-H1975 and NIH/3T3_TC32T8 cells, about 115- and 298-fold more sensitive than that of the inhibition of wild type EGFR in A431. (In Vivo):Oral administration of avitinib at daily dose of 500 mg/kg results in complete remission of tumors with EGFR active and T790M mutations for over 143 days with no weight loss. Three major metabolites of avitinib are tested and show no wild-type EGFR inhibition and off-target effects such as inhibition of IGF-1R. Avitinib is safe in non-small cell lung cancer (NSCLC) patients at the dose range between 50 mg and 550 mg once per day and no hyperglycemia and other severe adverse effects are detected such as grade 3 QT prolongation.
-
In VitroWestern Blot AnalysisCell Line:NCI-H1975, HCC827, A431 cells.Concentration:0.13 nM, 0.64 nM, 3.2 nM, 16 nM, 80 nM, 0.4 μM, 2 μM Incubation Time:2 h Result:Selectively inhibits mutant EGFR phosphorylation with IC50 values of 7.3 and 2.8 nM in NCI-H1975 and NIH/3T3_TC32T8 cells.
-
In VivoAnimal Model:Nu/Nu nude mice (Six- to 8-week-old) injected with NCI-H1975 and A431 cells Dosage:12.5, 50, and 500 mg/kg Administration:Orally administration; once daily; for 14 days Result:Inhibited EGFR-mutant tumor growth but not wild-type EGFR tumor growth.
-
SynonymsAC-0010 | AC0010
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number1557267-42-1
-
Formula Weight487.539
-
Molecular FormulaC26H26FN7O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 88 mg/mL (180.5 mM) ( < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESC=CC(NC1=CC=CC(OC2=C3C(NC=C3)=NC(NC4=CC=C(N5CCN(C)CC5)C(F)=C4)=N2)=C1)=O
-
Chemical NameN-[3-[[2-[[3-Fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]-2-propenamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xu X, et al. Mol Cancer Ther. 2016 Nov;15(11):2586-2597.
2. Wang W, et al. J Pharm Biomed Anal. 2017 May 30;139:205-214.
molnova catalog
related products
-
Afatinib dimaleate
An irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively.
-
Gefitinib hydrochlor...
A potent, selective, orally active EGFR inhibitor with IC50 of 23 nM.
-
WHI-P258
WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3.